Status:
RECRUITING
MCI Speech in Noise
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
Dartmouth College
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
55-80 years
Brief Summary
The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their bra...
Eligibility Criteria
Inclusion
- Adults diagnosed with or suspected to have MCI (for MCI group) or are cognitively normal (for Control group)
- Absence of other risk factors that might affect CAP (Central Auditory Processing) performance (e.g., active ear infections, congenital developmental delay, severe hearing loss)
- Age 55-80
- Normal hearing sensitivity (\<40 dB HL Pure Tone Average (average of 500, 1000, 2000 Hz) thresholds bilaterally
- Normal middle ear function defined by tympanometry (0.3-2.0 ml)
- Native English speaker
Exclusion
- Active ear infections or abnormal middle ear pathology
- Other health condition prohibiting the completion of the CAP test battery
- Mild to profound peripheral hearing loss (\>40 dB (decibel) HL (hearing loss) Pure Tone Average (average of 500, 1000, 2000 Hz) bilaterally
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- History of CNS (Central Nervous System) disorder that might severely impact cognitive function (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, neurosyphilis, intracranial tumors, history of significant head trauma with loss of consciousness (≥30 min), and cerebrovascular disease)
- Severe mental illness (e.g., schizophrenia, bipolar disorder)
- Current, uncontrolled medical condition that could affect cognition (e.g., hypertension)
- History of substance use disorder within the (other than nicotine/caffeine)
- Non-correctable severe hearing or vision loss
- Use of "Cognition Enhancing Drugs"
- Frequent, severe headaches (occasional headaches or migraines are fine)
Key Trial Info
Start Date :
May 18 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 2 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06102486
Start Date
May 18 2024
End Date
December 2 2025
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Space Medicine Lab at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756